⌘K
Loading ticker…
As of 2026-08-24, Immunovant, Inc. Common Stock (IMVT) has a 3-month relative strength percentile of 86 within the TickerStance CS+ADRC universe (~5,000 tickers). Its Power rating (absolute 1–99) is 74. The current market Stance is 47.8 (Neutral). Sector: Healthcare, ranked 3 of 11. Average daily range 3.7%, relative volume 1.08×. TickerStance reports observed regime conditions across the full CS+ADRC universe; band assignment reflects current breadth, momentum, and macro inputs computed at the daily close. Percentile ranks run from 1 (weakest) to 99 (strongest) relative to all universe members on the same date.
IMVT is in a stage 2 uptrend, week 12. Extended from base. VCP detected: inconclusive. Distance from 50d / 200d: 9.7% / 45.6%.
Relative strength across horizons plus the leadership score.
Accumulation rating, relative volume, U/D ratio, breakout-day proof.
Diluted EPS, last 8 quarters. Loss makers are judged by progress toward breakeven.
IMVT is held by 22 ETFs as of May 2026. Top owner: VTWO at 0.08% weight, $14M notional. Top 3 carry $34M.
Held by 56 ETFs · $363M across latest filings · largest weight 1.11% (GURU).
Top 10 by value, from SEC N-PORT-P filings dated May 2026.
| ETF | Weight | Value | Δ |
|---|---|---|---|
| VTWO | 0.08% | $14M | +0.02 pp |
| SCHASchwab U.S. Small-Cap ETF | 0.05% | $12M | — |
| VHTVanguard Health Care ETF | 0.04% | $8M | — |
| VTWG | 0.15% | $3M | +0.03 pp |
| ONEQ | 0.02% | $2M | — |
Strong relative strength, but attention is quiet relative to this name’s own recent norm. Academic work links low public attention to better forward returns on average — context to weigh, not a forecast.
Measures how unusual this name’s public attention is against its own 90-day history — a surprise reading, not a ranking of how watched it is versus other stocks. Intel, not a signal.
News
Daily range, ATR, beta, and the math for a 1-ADR stop.
YoY sales growth, last 8 quarters. Sales must back the earnings story.
Operating margin unavailable
YoY common shares outstanding. Down = buyback tailwind. Up > 2% = dilution flag.
Reported figures from SEC filings. No analyst estimates or forward guidance.
| 0.00% |
| $1M |
| — |
| VFMO | 0.05% | $950K | — |
| ESGV | 0.00% | $606K | — |
| IBBQ | 0.54% | $363K | +0.18 pp |
| BIB | 0.34% | $251K | +0.10 pp |
Showing 10 of 22 ETF owners.
As filed in N-PORT — quarterly holdings with up to ~60-day publication lag. Not live positioning.
Related searches
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | IMVT Jan avg: -5.85% median: -6.06% win: 50% σ: 8.21% n: 4 2022-04-12 → 2026-07-31 | IMVT Feb avg: -0.78% median: -2.27% win: 25% σ: 5.17% n: 4 2022-04-12 → 2026-07-31 | IMVT Mar avg: -11.83% median: -10.82% win: 0% σ: 3.63% n: 4 2022-04-12 → 2026-07-31 | IMVT Apr avg: -2.82% median: -5.50% win: 40% σ: 9.59% n: 5 2022-04-12 → 2026-07-31 | IMVT May avg: 5.86% median: -7.47% win: 40% σ: 18.96% n: 5 2022-04-12 → 2026-07-31 | IMVT Jun avg: 1.94% median: 3.98% win: 60% σ: 10.75% n: 5 2022-04-12 → 2026-07-31 | IMVT Jul avg: 7.37% median: 5.64% win: 100% σ: 8.32% n: 5 2022-04-12 → 2026-07-31 | IMVT Aug avg: 5.53% median: 2.89% win: 50% σ: 14.34% n: 4 2022-04-12 → 2026-07-31 (current) | IMVT Sep avg: 19.85% median: 9.04% win: 75% σ: 33.74% n: 4 2022-04-12 → 2026-07-31 | IMVT Oct avg: 35.63% median: 27.87% win: 75% σ: 51.91% n: 4 2022-04-12 → 2026-07-31 | IMVT Nov avg: 7.42% median: 7.45% win: 50% σ: 11.93% n: 4 2022-04-12 → 2026-07-31 | IMVT Dec avg: 9.04% median: 6.46% win: 75% σ: 19.67% n: 4 2022-04-12 → 2026-07-31 |